GLP-1 Lab Monitoring: The Panel and Cadence to Track

The Core Panel at a Glance

The single most useful table on this page is the panel itself. Below is the set of biomarkers commonly monitored on GLP-1 therapy, why each tends to matter in this context, and the typical timing people discuss with their clinicians. Treat the timing column as a common pattern, not a rule. Your prescriber may test more or less often based on your individual situation.

|---|---|---|

The rest of this guide walks through each cluster so the table reads as more than a list. For drug-specific detail, the [semaglutide blood work guide](/blog/semaglutide-blood-work-guide) and the [tirzepatide blood work guide](/blog/tirzepatide-blood-work-guide) go deeper on each medication, and the full [biomarker library](/biomarkers) has plain-language explanations of every test named here.

Why a Baseline Comes First

Almost every conversation about GLP-1 monitoring starts in the same place: get a clean baseline before anything changes. The reason is simple. The entire value of monitoring is the comparison, and you cannot compare against a number you never recorded. A baseline panel captures where your metabolic, lipid, liver, kidney, and nutritional markers sit at the starting line, so that the 3-month and 6-month draws have something to be measured against.

This is also where the trend-over-snapshot idea earns its keep. A single ApoB or single ALT value tells you very little on its own, because individual results carry day-to-day variation and depend on factors like fasting state, hydration, and recent activity. A baseline followed by consistent re-tests turns scattered data points into a line you and your clinician can actually read. That is the core of what MyProtocolStack is built to do: keep every result in one place so the direction of travel is visible, not buried in a folder of PDFs.

The Metabolic Markers: HbA1c, Glucose, and Insulin

The metabolic cluster is where GLP-1 therapy is most directly relevant. [HbA1c](/biomarkers/hba1c) reflects roughly three months of average blood glucose, which makes it well suited to a quarterly cadence. [Fasting glucose](/biomarkers/fasting-glucose) adds a point-in-time read that complements the longer HbA1c average, and [fasting insulin](/biomarkers/fasting-insulin) speaks to insulin sensitivity, a measure researchers lean on heavily in metabolic studies.

Tracking all three together gives a more complete view than any one alone. Because HbA1c integrates over about 90 days, testing it more often than quarterly rarely adds information, which is part of why the common pattern lands on baseline, then roughly 3 and 6 months. If you want a deeper walk-through of what HbA1c represents and how it is read, the biomarker library entry for [HbA1c](/biomarkers/hba1c) covers it in plain language.

The Lipid Panel: ApoB, Triglycerides, HDL, and LDL

Lipids are the second major cluster, and they are worth doing as a full panel rather than a single number. [ApoB](/biomarkers/apob) has drawn growing attention because it counts atherogenic particles directly rather than estimating cholesterol mass, and it often shifts as body composition changes. Alongside it, [triglycerides](/biomarkers/triglycerides) tend to improve as weight decreases, which makes them a sensitive marker to watch on a trend line, while [HDL](/biomarkers/hdl-c) and [LDL](/biomarkers/ldl-c) round out the conventional picture.

A practical note that comes up repeatedly: lipids and triglycerides tend to move in a favorable direction as weight comes down, so the full panel is a natural fit for the same 3 and 6 month checkpoints used for the metabolic markers. Most lipid panels are drawn fasting, so coordinating them with your fasting glucose and insulin in a single morning draw is efficient. For the difference between ApoB and standard LDL reporting, our explainer on [ApoB versus LDL](/blog/apob-vs-ldl) breaks it down without jargon.

The Liver Markers: ALT and AST

Liver enzymes are commonly followed during GLP-1 weight loss because they reflect a part of metabolic health that often changes meaningfully as weight comes down. [ALT](/biomarkers/alt) is the marker most often discussed here, with [AST](/biomarkers/ast) tracked alongside it for a fuller view. A useful specific that appears in the literature: improvements in ALT during GLP-1 weight loss tend to plateau around week 30, which is one reason the 3-month and 6-month checkpoints capture most of the relevant movement.

Because the liver markers tell a story that unfolds over months rather than days, they belong on the same quarterly-then-periodic rhythm as the rest of the panel. If you want a focused, step-by-step treatment of these two enzymes in the context of a protocol, see our guide on [how to monitor liver enzymes on a protocol](/blog/how-to-monitor-liver-enzymes-on-protocol), and the [ALT](/biomarkers/alt) and [AST](/biomarkers/ast) library entries explain what each enzyme is and why both are drawn.

The Kidney Markers: eGFR and Creatinine

Kidney function rounds out the safety-relevant side of the panel. [eGFR](/biomarkers/egfr) estimates how well the kidneys are filtering, and [creatinine](/biomarkers/creatinine) is the blood value that feeds the eGFR calculation, so the two are read together. The reason renal markers come up in GLP-1 discussions is mechanical rather than mysterious: the gastrointestinal side effects that some people experience, such as nausea or reduced fluid intake, can lead to dehydration, and dehydration can transiently affect kidney-function readings.

That is precisely why a trend line is more informative than a single result here. A one-off eGFR drawn on a day of poor hydration reads differently than the same marker on a well-hydrated day, and only a series of values in context tells the real story. Keeping creatinine and eGFR side by side over time, which a tracking tool makes easy, helps separate a passing blip from a genuine trend worth raising with your clinician.

Thyroid Context and the Boxed Warning

[TSH](/biomarkers/tsh) appears on the commonly tracked list partly for general thyroid context and partly because of a specific labeling fact worth understanding plainly. GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors, including medullary thyroid carcinoma, based on findings reported in rodents. The relevance of those rodent findings to humans is not established, and the warning is a labeling and screening-context matter, not a diagnosis of anything. We mention it because it is part of why thyroid is discussed in this category at all, and any question about it belongs with your prescriber, who can place it in the context of your personal and family history.

This is a good moment to restate the boundary this article operates within. Naming a boxed warning is reporting a labeled fact, not interpreting your individual risk. MyProtocolStack does not assess that risk, and nothing here substitutes for the screening and history-taking your clinician performs.

The Nutritional and Inflammation Markers

The final cluster reflects a predictable consequence of appetite change. Because GLP-1 medications reduce appetite, intake of certain nutrients can fall, which is why [vitamin B12](/biomarkers/vitamin-b12) and [vitamin D](/biomarkers/vitamin-d) are commonly followed as nutritional-status markers over time. A complete blood count (CBC) is typically included as a general baseline as well. On the inflammation side, [hs-CRP](/biomarkers/hs-crp) is a high-sensitivity marker that often moves alongside metabolic change, which makes it a natural companion to the metabolic and lipid clusters.

None of these is a marker you would chase week to week. The value is in periodic checks layered onto the same record as everything else, so that a slow drift in B12 or vitamin D shows up as a visible slope rather than a surprise. For vitamin D specifically, our [vitamin D optimization](/blog/vitamin-d-optimization) explainer covers what the test measures and how it is commonly read.

Putting the Cadence Together

Stepping back, the commonly discussed rhythm is straightforward: a full baseline before starting, follow-up panels at roughly 3 and 6 months, and periodic re-testing after that. The 3 and 6 month checkpoints exist because most of the markers in this panel, from HbA1c to ALT to the lipid set, tell their story over a span of months. Testing far more often than that usually adds noise rather than signal, while testing far less often risks missing a trend worth discussing.

The throughline across every cluster is the same one MyProtocolStack is built around: a trend beats a snapshot every time. A single value is a moment; a series is a direction. Keeping each result in one organized place is what turns a pile of lab PDFs into something you and your clinician can actually read together. Monitoring decisions, what to test and how often, are made with your prescriber. The job of a tracking tool is to make sure that when you have that conversation, the data is clean, complete, and ready.

[Track your GLP-1 labs over time in one place with MyProtocolStack.](/auth/login?mode=signup)

Frequently Asked Questions

What labs should I get before starting a GLP-1?

A common approach is a full baseline panel before starting, so later results have something to be compared against. The biomarkers people frequently track include HbA1c, fasting glucose, and fasting insulin for metabolic health; a full lipid panel with ApoB, triglycerides, HDL, and LDL; ALT and AST for the liver; eGFR and creatinine for the kidneys; TSH for thyroid context; a CBC; and vitamin B12, vitamin D, and hs-CRP. The exact panel is set by your prescriber. This is educational, not a prescription.

How often should labs be checked on semaglutide or tirzepatide?

The commonly discussed cadence is a baseline before starting, follow-up at roughly 3 and 6 months, and periodic re-testing after that. Many markers in the panel, such as HbA1c and the liver enzymes, reflect changes that unfold over months, which is why a quarterly-then-periodic rhythm is typical. Your clinician may test more or less often based on your individual situation.

Why are liver enzymes monitored on a GLP-1?

ALT and AST reflect a part of metabolic health that often changes as weight comes down, so they are commonly followed during GLP-1 weight loss. One reported specific is that ALT improvements during GLP-1 weight loss tend to plateau around week 30, which is part of why the 3 and 6 month checkpoints capture most of the relevant movement. Any interpretation of your results belongs with your clinician.

Why are kidney markers like eGFR watched?

Kidney function is followed because the gastrointestinal side effects some people experience on GLP-1 medications, such as nausea or reduced fluid intake, can lead to dehydration, which can transiently affect kidney-function readings. Tracking creatinine and eGFR over time helps distinguish a passing blip from a genuine trend, which is a conversation to have with your provider.

Can MyProtocolStack tell me if my results are normal?

No. MyProtocolStack organizes and visualizes your lab results over time so you can see trends, but it does not interpret your numbers, diagnose, or treat, and it does not replace medical oversight. Monitoring decisions and the meaning of any specific result are made with your prescriber or provider.

Sources

1. Mochi Health, "What Labs Should You Monitor on GLP-1s? A Complete Biomarker Guide." https://joinmochi.com/blog/what-labs-should-you-monitor-on-glp-1s-a-complete-biomarker-guide

2. Choose Health, "GLP-1 and Your Liver: What Enzyme Levels to Monitor on Weight Loss Medications." https://www.choosehealth.io/articles/glp-1-and-your-liver-what-enzyme-levels-to-monitor-on-weight-loss-medications

3. National Center for Biotechnology Information, PMC, comparative GLP-1 safety review (gastrointestinal, renal, and pancreatic considerations). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12845133/

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*